Scalable yeast bioproduction of structurally distinct peptides
A novel yeast-based platform for producing and secreting a wide range of structurally distinct peptides, including cyclic and antimicrobial peptides, with applications in medicine and agriculture.
Overview
This innovative platform utilizes yeast cells to produce and secrete structurally distinct peptides, such as cyclic, disulfide-rich, and antimicrobial peptides. These peptides hold significant potential in medical and agricultural applications, offering a sustainable and scalable solution for peptide production. The platform enables large-scale secretion of peptides into spent media, facilitating easy purification and post-translational modifications.
Technical specifications
Key features:
- Utilizes yeast cells for peptide production and secretion
- Supports production of complex peptides like chlorotoxin and antimicrobial peptides
- Allows for intricate post-translational modifications, including cyclization and conjugation
- Employs a 'one-pot' solution for chemical or enzymatic ligations
- Optimizes bioreactor conditions using small-scale fermentors for scalable production
Technology readiness level
This platform is currently at Technology Readiness Level 3, indicating it has been experimentally validated and is in the active development stage to enhance its capabilities and scalability.
About The University of Queensland
The University of Queensland is a large, multi-campus public research university in Brisbane with a comprehensive academic and research profile. Industry partners engage through hospital-embedded laboratories and clinical sites, pilot testbeds, and field campuses across Queensland that enable prototyping, trials, and validation in real-world settings. Co-location with major health precincts and proximity to Brisbane’s innovation districts make collaboration and talent access straightforward, while on-campus incubation and professional education support workforce upskilling. Research is supported by competitive national funding from the Australian Research Council and the National Health and Medical Research Council, alongside state and industry investment. A dedicated technology transfer office and commercialization company manage IP, licensing, sponsored research agreements, and spin-out formation.
delivered to your inbox.